Transforming growth factor beta receptor-SMAD3 signaling axis (TGFBR-SMAD3 axis)

The Transforming growth factor beta (TGF-beta) receptor to SMAD3 signaling axis is a fundamental pathway that converts extracellular TGF-beta signals into transcriptional responses (UniProt P36897, P84022). Signaling is initiated when TGF-beta ligands bind to the TGF-beta type II receptor (TGFBR2), which then recruits and activates the TGF-beta type I receptor (TGFBR1/ALK5). The activated type I receptor phosphorylates SMAD3, a key intracellular mediator that translocates to the nucleus to regulate gene expression (PubMed: 29129918). This axis plays a critical role in maintaining tissue homeostasis but is frequently dysregulated in diseases such as cancer and organ fibrosis. In the context of malignancy, the pathway promotes the epithelial-mesenchymal transition (EMT), enhancing tumor invasion and suppressing the anti-tumor immune response (PubMed: 30635915). In fibrotic conditions, the axis drives the activation of myofibroblasts and the overproduction of extracellular matrix components. Pharmacological targeting of this axis involves small molecule inhibitors of the TGFBR1 kinase or biologics that sequester TGF-beta ligands. Clinical development of these agents faces challenges such as potential cardiotoxicity and the dual role of TGF-beta as both a tumor suppressor and a promoter (PubMed: 28115549).

Other names

TGF-beta/SMAD3 pathwayTGFB-SMAD3 signaling axisTGFBR1-SMAD3 axisALK5-SMAD3 pathway

Inhibition of TGF-beta receptor type 1 (ALK5) kinase activity or ligand sequestration, preventing the phosphorylation and nuclear translocation of SMAD3 to block downstream gene transcription.